Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.85.EBIT: As of FY2026 Q1, the actual value is USD -2.781 M.Silexion Therapeutics Corp has not generated any revenue from product sales to date.<h4>Operational Metrics (Three Months Ended March 31)</h4><ul><li>Net Loss:<ul><li>2026: -$2,733 thousand</li><li>2025: -$1,735 thousand</li></ul></li><li>Operating Loss:<ul><li>2026: -$2,749 thousand</li><li>2025: -$1,650 thousand</li></ul></li><li>Research and Development Expenses:<ul><li>2026: $1,370 thousand, an increase of 133.3% from $590 thousand in 2025. This increase was mainly due to a $700 thousand rise in subcontractors and consultants expenses for toxicology studies and product development, including GMP manufacturing, to support planned human clinical trials, and a $100 thousand increase in share-based compensation expenses related to executive officers’ grants.</li><li>Key components for 2026 included: Payroll and related expenses ($263 thousand), Share-based compensation expenses ($130 thousand), Subcontractors and consultants ($891 thousand), Rent and maintenance ($55 thousand), and Other ($31 thousand).</li></ul></li><li>General and Administrative Expenses:<ul><li>2026: $1,379 thousand, an increase of 27.3% from $1,060 thousand in 2025. This increase was primarily driven by a $300 thousand rise in professional services (legal, investor relations, press release activities, director compensation) and a $200 thousand increase in share-based compensation expenses related to equity grants to executive officers and directors.</li><li>Key components for 2026 included: Payroll and related expenses ($241 thousand), Share-based compensation expenses ($215 thousand), Professional service ($783 thousand), Depreciation ($2 thousand), Rent and maintenance ($49 thousand), Patent registration ($8 thousand), and Other ($81 thousand).</li></ul></li><li>Financial Expenses (Income), Net:<ul><li>2026: -$16 thousand</li><li>2025: $85 thousand</li><li>The decrease was mainly due to a reduction in revaluation expenses of financial instruments, primarily promissory notes.</li></ul></li></ul><h4>Cash Flow (Three Months Ended March 31)</h4><ul><li>Net Cash Used in Operating Activities:<ul><li>2026: -$3,646 thousand, an increase of 44.0% from -$2,453 thousand in 2025. This increase was largely due to higher prepayments for R&amp;D product development subcontractors and consultants, particularly for GMP batch manufacturing.</li></ul></li><li>Net Cash Used in Investing Activities:<ul><li>2026: $0</li><li>2025: -$6 thousand</li></ul></li><li>Net Cash Provided by Financing Activities:<ul><li>2026: $83 thousand</li><li>2025: $7,432 thousand</li><li>The significant decrease was primarily because only $83 thousand (net of sales agent fees) was raised via the At-The-Market (ATM) facility in 2026, compared to $5 million from the January 2025 Offering, $0.9 million from warrant exercises, and $3.3 million from a warrant inducement transaction in 2025, partially offset by $0.7 million in cash payments for the EarlyBird Convertible Note in 2025.</li></ul></li><li>Cash and Cash Equivalents:<ul><li>As of March 31, 2026: $2,413 thousand</li></ul></li></ul><h4>Other Key Financial Metrics</h4><ul><li>Accumulated Deficit: As of March 31, 2026, the accumulated deficit was -$57,899 thousand.</li><li>Shareholders’ Equity: As of March 31, 2026, shareholders’ equity was $291 thousand. Following May 2026 transactions, it was restored to $2.6 million.</li><li>Related Party Promissory Note: The principal amount outstanding was $1,633 thousand as of March 31, 2026. After May 2026 conversions, this balance was reduced to $1,229 thousand.</li><li>Israeli Innovation Authority (IIA) Grants: Silexion Therapeutics Corp received royalty-bearing grants totaling approximately $5.8 million, with a potential royalty amount payable of $5.8 million ($6.8 million including interest).</li></ul><h4>Future Outlook and Strategy</h4>Silexion Therapeutics Corp expects to continue incurring significant operating losses and negative cash flows, requiring additional capital for operations, business expansion, and Nasdaq listing compliance. The company plans to initiate clinical studies for its lead product candidate, SIL204, in the second quarter of 2026, contingent on regulatory clearance, and intends to pursue additional financing through its ATM facility, which has $12.0 million remaining available, and potential public offerings. To address Nasdaq listing requirements, the company approved an increase in authorized share capital and plans a 1-for-10 reverse share split in late May or early June 2026 to raise its share price.

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 0